Page last updated: 2024-08-22

angiotensin ii and everolimus

angiotensin ii has been researched along with everolimus in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ahonen, J; Finckenberg, P; Ganten, D; Inkinen, K; Louhelainen, M; Luft, F; Merasto, S; Mervaala, E; Müller, D; Vapaatalo, H	1
Bieri, M; Farkas, A; Ligeti, N; Marti, HP; Meier, B; Mohacsi, P; Oroszlán, M	1
Golledge, J; Jose, RJ; Körner, H; Moran, CS; Moxon, JV; Norman, PE; Roomberg, A; Rush, C	1
Betz, MJ; Beuschlein, F; Burkard, T; Cavelti-Weder, C; Donath, MY; Hall, MN; Hepprich, M; Kratschmar, DV; Meienberg, F; Odermatt, A; Reincke, M; Seelig, E; Swierczynska, MM; Trinh, B	1

Trials

1 trial(s) available for angiotensin ii and everolimus

Article	Year
Treatment of Primary Aldosteronism With mTORC1 Inhibitors. The Journal of clinical endocrinology and metabolism, 2019, 10-01, Volume: 104, Issue:10 Topics: Adult; Aldosterone; Angiotensin II; Animals; Blood Pressure; Everolimus; Female; Hemodynamics; Humans; Hyperaldosteronism; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, 129 Strain; Mice, Inbred BALB C; Mice, Inbred C57BL; Middle Aged; Pilot Projects; Proof of Concept Study; Renin; Sirolimus	2019

Article

Year

Treatment of Primary Aldosteronism With mTORC1 Inhibitors.

The Journal of clinical endocrinology and metabolism, 2019, 10-01, Volume: 104, Issue:10

Topics: Adult; Aldosterone; Angiotensin II; Animals; Blood Pressure; Everolimus; Female; Hemodynamics; Humans; Hyperaldosteronism; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, 129 Strain; Mice, Inbred BALB C; Mice, Inbred C57BL; Middle Aged; Pilot Projects; Proof of Concept Study; Renin; Sirolimus

2019

Other Studies

3 other study(ies) available for angiotensin ii and everolimus

Article	Year
Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways. The American journal of pathology, 2003, Volume: 163, Issue:1 Topics: Angiotensin II; Animals; Blood Pressure; Calcineurin; Collagen Type I; Collagen Type III; Connective Tissue Growth Factor; Cyclosporine; Everolimus; Gene Expression Regulation; Heart; Humans; Immediate-Early Proteins; Immunosuppressive Agents; In Situ Hybridization; Intercellular Signaling Peptides and Proteins; Kidney; Male; Organisms, Genetically Modified; Rats; Rats, Sprague-Dawley; Renin; Sirolimus; Transforming Growth Factor beta; Transforming Growth Factor beta1	2003
Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway. Transplant immunology, 2010, Volume: 23, Issue:3 Topics: Albumins; Angiotensin II; Cell Line; Down-Regulation; Drug Therapy, Combination; Endocytosis; Epithelial Cells; Everolimus; Humans; Immunosuppressive Agents; Kidney Tubules, Proximal; Losartan; Low Density Lipoprotein Receptor-Related Protein-2; Ramipril; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; Signal Transduction; Sirolimus	2010
Everolimus limits aortic aneurysm in the apolipoprotein E-deficient mouse by downregulating C-C chemokine receptor 2 positive monocytes. Arteriosclerosis, thrombosis, and vascular biology, 2013, Volume: 33, Issue:4 Topics: Angiotensin II; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Apolipoproteins E; Cell Movement; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Everolimus; Flow Cytometry; Infusion Pumps, Implantable; Infusions, Subcutaneous; Interferon-gamma; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Monocytes; Protein Kinase Inhibitors; Receptor, Macrophage Colony-Stimulating Factor; Receptors, CCR2; Sirolimus; TOR Serine-Threonine Kinases	2013